← Guangdong Zhongsheng Pharmaceutical overview

Guangdong Zhongsheng Pharmaceutical vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Guangdong Zhongsheng Pharmaceutical Co Ltd (002317.CS)

Q3 202620 Jul – 8 Oct 2026

▲3▼1

Zhongsheng's weight-loss drug hits Phase III goal, but profit slumps

RAY1225 weight-loss trial succeeds The company's once-every-two-weeks weight-loss injection RAY1225 met the main goal of its late-stage trial, cutting body weight by 22.24% with good safety. This is the biggest value driver: it raises the odds of a future blockbuster obesity drug, though approval is still not guaranteed.
The Phase III success is the strongest new catalyst for the stock's long-term value.
MASH drug gets fast-track review ZSP1601 tablets for fatty liver disease (MASH) were accepted into China's breakthrough therapy program after positive mid-stage data showing less liver scarring and fat. Fast-track status can speed up approval and signals the drug is promising, supporting the company's pipeline value.
A new regulatory milestone for a second innovative drug adds to the pipeline story.
Interim profit falls 40.7% First-half 2026 net profit dropped 40.70% to 111 million yuan and revenue fell 23.03% to 1 billion yuan. The existing business is shrinking, which is a real counterweight: the exciting pipeline news does not yet pay the bills, and weak earnings can cap the stock.
The profit decline is the main negative force and the honest counterweight to the pipeline optimism.
New eye-drop approval and Japan patent Zhongsheng won Chinese approval to sell its allergy eye drop Emedastine Difumarate, a small but real new revenue source. It also secured the core Japanese patent for RAY1225, strengthening long-term protection of its key obesity drug in a major market.
These are smaller but concrete new positives on top of the pipeline news.

August 202620 Jul – 8 Oct 2026

▲3▼1

Zhongsheng's weight-loss drug hits Phase III goal, but profit slumps

RAY1225 weight-loss trial succeeds The company's once-every-two-weeks weight-loss injection RAY1225 met the main goal of its late-stage trial, cutting body weight by 22.24% with good safety. This is the biggest value driver: it raises the odds of a future blockbuster obesity drug, though approval is still not guaranteed.
The Phase III success is the strongest new catalyst for the stock's long-term value.
MASH drug gets fast-track review ZSP1601 tablets for fatty liver disease (MASH) were accepted into China's breakthrough therapy program after positive mid-stage data showing less liver scarring and fat. Fast-track status can speed up approval and signals the drug is promising, supporting the company's pipeline value.
A new regulatory milestone for a second innovative drug adds to the pipeline story.
Interim profit falls 40.7% First-half 2026 net profit dropped 40.70% to 111 million yuan and revenue fell 23.03% to 1 billion yuan. The existing business is shrinking, which is a real counterweight: the exciting pipeline news does not yet pay the bills, and weak earnings can cap the stock.
The profit decline is the main negative force and the honest counterweight to the pipeline optimism.
New eye-drop approval and Japan patent Zhongsheng won Chinese approval to sell its allergy eye drop Emedastine Difumarate, a small but real new revenue source. It also secured the core Japanese patent for RAY1225, strengthening long-term protection of its key obesity drug in a major market.
These are smaller but concrete new positives on top of the pipeline news.

Latest20 Jul – 8 Oct 2026

▲3▼1

Zhongsheng's weight-loss drug hits Phase III goal, but profit slumps

RAY1225 weight-loss trial succeeds The company's once-every-two-weeks weight-loss injection RAY1225 met the main goal of its late-stage trial, cutting body weight by 22.24% with good safety. This is the biggest value driver: it raises the odds of a future blockbuster obesity drug, though approval is still not guaranteed.
The Phase III success is the strongest new catalyst for the stock's long-term value.
MASH drug gets fast-track review ZSP1601 tablets for fatty liver disease (MASH) were accepted into China's breakthrough therapy program after positive mid-stage data showing less liver scarring and fat. Fast-track status can speed up approval and signals the drug is promising, supporting the company's pipeline value.
A new regulatory milestone for a second innovative drug adds to the pipeline story.
Interim profit falls 40.7% First-half 2026 net profit dropped 40.70% to 111 million yuan and revenue fell 23.03% to 1 billion yuan. The existing business is shrinking, which is a real counterweight: the exciting pipeline news does not yet pay the bills, and weak earnings can cap the stock.
The profit decline is the main negative force and the honest counterweight to the pipeline optimism.
New eye-drop approval and Japan patent Zhongsheng won Chinese approval to sell its allergy eye drop Emedastine Difumarate, a small but real new revenue source. It also secured the core Japanese patent for RAY1225, strengthening long-term protection of its key obesity drug in a major market.
These are smaller but concrete new positives on top of the pipeline news.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.